A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
AstraZeneca
M.D. Anderson Cancer Center
Qilu Pharmaceutical Co., Ltd.
Eli Lilly and Company
Merck Sharp & Dohme LLC
Incyte Corporation
Merck Sharp & Dohme LLC